Breaking Gene Therapy News
-
Early Data for bluebird bio Gene-Therapy Candidate Show Some Promise - Genetic Engineering & Biotechnology News
Jun 23, 2017 | 17:01 pmEarly Data for bluebird bio Gene-Therapy Candidate Show Some PromiseGenetic Engineering & Biotechnology Newsbluebird bio today disclosed its first data, including some promising results, from a pair of clinical studies assessing its LentiGlobin™ gene therapy candidate—including a Phase III study that followed a change in its manufacturing process. In the ...and more »
Read more... -
Bluebird Bio rebuilds case for blood disorder gene therapy - FierceBiotech
Jun 23, 2017 | 16:33 pmFierceBiotechBluebird Bio rebuilds case for blood disorder gene therapyFierceBiotechBluebird Bio reported encouraging data on its revamped gene therapy for sickle cell disease (SCD) and beta thalassemia this morning, but shares slipped 6% premarket on some unresolved issues. Two years ago, Bluebird was hit hard when a trial of its ...and more »
Read more... -
Novartis-backed GenSight gets cash for gene therapy launch - FierceBiotech
Jun 23, 2017 | 15:39 pmFierceBiotechNovartis-backed GenSight gets cash for gene therapy launchFierceBiotechParis-based GenSight raised the cash from a mix of new and existing institutional investors. Share Facebook Twitter LinkedIn Email Print. GenSight Biologics has raised (PDF) €22.5 million ($25.2 million) to prepare to bring gene therapy GS010 to market ...and more »
Read more... -
Sarepta Signs Gene Therapy R&D Deal for DMD - Drug Discovery & Development
Jun 23, 2017 | 14:14 pmDrug Discovery & DevelopmentSarepta Signs Gene Therapy R&D Deal for DMDDrug Discovery & DevelopmentSarepta Therapeutics is expanding its arsenal of drug development initiatives aimed at finding a treatment for Duchenne muscular dystrophy (DMD). The biopharmaceutical company will collaborate with Genethon, a non-profit R&D organization to jointly ...and more »
Read more... -
French Biotech Raises Over €22M to Launch a Gene Therapy to Restore Sight - Labiotech.eu (blog)
Jun 23, 2017 | 13:57 pmLabiotech.eu (blog)French Biotech Raises Over €22M to Launch a Gene Therapy to Restore SightLabiotech.eu (blog)Gensight Biologics has announced a capital increase that totals €22.5M and will support the launch of its gene therapy for blindness in Europe and the US. Gensight has decided to give an additional financial push to its lead candidate, GS010, a gene ...and more »
Read more... -
Bluebird Bio's gene therapy for blood disorders yields some ... - STAT
Jun 23, 2017 | 13:10 pmSTATBluebird Bio's gene therapy for blood disorders yields some ...STATBluebird Bio's trial of a gene therapy for two inherited blood disorders yielded some impressive results Friday ― but also raised key questions.and more »
Read more... -
Bluebird Reports Early Results From Upgraded Gene Therapy - Xconomy
Jun 23, 2017 | 13:05 pmXconomyBluebird Reports Early Results From Upgraded Gene TherapyXconomyOne of the year's most closely watched clinical studies could lead to a landmark approval of a gene therapy and throw wide open the debate over how to pay for expensive drugs. The first drips of data have emerged. Bluebird Bio (NASDAQ: BLUE) says the ...and more »
Read more... -
Bluebird bio steps up with a promising snapshot of its gene therapy upgrade - Endpoints News
Jun 23, 2017 | 13:02 pmEndpoints NewsBluebird bio steps up with a promising snapshot of its gene therapy upgradeEndpoints NewsAs a pioneer in the new wave of gene therapy treatments that have been steadily winding their way toward regulators with the promise of a once-and-done genetic fix for a wide range of ailments, bluebird bio $BLUE also got the first taste of the kind of ...and more »
Read more... -
Global Gene Immunization Therapy Market Trends, Challenges and Growth Drivers Analysis 2022 - Medgadget (blog)
Jun 23, 2017 | 09:33 amMedgadget (blog)Global Gene Immunization Therapy Market Trends, Challenges and Growth Drivers Analysis 2022Medgadget (blog)“Global Gene Immunization Therapy Market Research Report 2017”Purchase This Report by calling ResearchnReports.com at +1-888-631-6977. In this report the Global Gene Immunization Therapy market, aims at discovering key statistical and factual ...and more »
Read more... -
Sarepta and Genethon Will Collaborate to Develop DMD Gene Therapy - Muscular Dystrophy News
Jun 22, 2017 | 17:01 pmSarepta and Genethon Will Collaborate to Develop DMD Gene TherapyMuscular Dystrophy NewsSarepta Therpeutics and Genethon have signed a research collaboration agreement to jointly develop a gene therapy for Duchenne muscular dystrophy (DMD). Created by the AFM-Telethon, the French Muscular Dystrophy Association, Genethon is a ...and more »
Read more...